Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK adopts military technology adapted to diagnose chlamydia:

This article was originally published in Clinica

Executive Summary

The UK treasury is giving the Porton Down branch of the Department of Science and Technology Laboratory (Dstl) and the Department of Health £4.6m ($6.6m) to provide hospital labs and clinics with a chlamydia screening device that Dstl has created by adapting existing military technology. The technology, initially designed to track biological warfare agents, will enable the NHS to obtain accurate results within 40 minutes compared with the previous standard of a fortnight, thus saving the NHS "millions", claims Dstl. Chlamydia affects 10% of women aged between 16 and 24.

You may also be interested in...



Sanofi Skates To Where The Puck Is With Immunology

The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.

Pipeline Watch: Five Approvals And 23 Phase III Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT066717

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel